<DOC>
	<DOCNO>NCT01599897</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , immunogenicity healthy adult subject investigational vaccine develop prevention pulmonary tuberculosis . The vaccine , identify ID93 + GLA-SE , consist recombinant four-antigen Mycobacterium tuberculosis recombinant protein ID93 together adjuvant GLA-SE .</brief_summary>
	<brief_title>Phase 1 ID93 + GLA-SE Vaccine Trial Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Has complete write informed consent process prior start screen evaluation Male female 18 45 year age time randomization Agrees stay contact study site duration study , provide update contact information necessary , current plan move study area duration study Agrees avoid elective surgery full duration study For female subject : agree avoid pregnancy Study Day 238 . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy period . Acceptable method avoid pregnancy include sterile sexual partner , sexual abstinence ( engage sexual intercourse ) , hormonal contraceptive ( oral , injection , transdermal patch , implant ) , vaginal ring , intrauterine device ( IUD ) , condoms combination diaphragm spermicide Has body mass index ( BMI ) 19 33 ( weight/height2 ) nomogram time randomization Acute illness time randomization Oral temperature great 37.5C ( 99.5F ) time randomization Values follow screen laboratory parameter , blood collect within 15 day prior randomization , outside normal range per local laboratory parameter : hemoglobin , hematocrit , absolute neutrophil count , absolute lymphocyte count , white blood cell count , electrolytes , ALT , AST , total bilirubin , alkaline phosphatase ( ALP ) , creatinine , BUN , lipid profile Evidence systemic local disease process screen urinalysis Evidence significant active infection Positive laboratory test ( e.g. , QuantiFERON ( R ) TB ) evidence Mtb infection screen History treatment active latent tuberculosis infection History evidence active tuberculosis Has receive vaccination immunotherapy BCG product time prior randomization Shared residence within last year prior randomization individual antituberculosis treatment culture smear positive tuberculosis History evidence current hypertension History autoimmune disease immunosuppression Used immunosuppressive medication within 42 day randomization ( inhaled topical corticosteroid permit ) Received immunoglobulin blood product within 42 day randomization Received investigational drug therapy investigational vaccine within 182 day randomization , plan participation investigational study study period Received investigational Mtb vaccine time prior randomization Unable discontinue current chronic prescription drug therapy include hormone replacement thyroxin , insulin , medication hepatotoxic toxic bone marrow ( statin ) etc ( estrogen progesterone replacement contraceptive , topical medication , nasal steroid acceptable ) History laboratory evidence immunodeficiency state include limited laboratory indication HIV 1 infection screen History allergic disease reaction ( allergic reaction egg ) , include eczema , likely exacerbate component study vaccine History allergic reaction kanamycinrelated antibiotic Previous medical history may compromise safety subject study , include limited : severe impairment pulmonary function tuberculosis infection pulmonary disease ; chronic illness sign cardiac renal failure ; suspect progressive neurological disease ; uncontrolled epilepsy infantile spasms History positive tuberculin skin test Evidence chronic hepatitis ( e.g. , hepatitis B core antibody hepatitis C antibody ) screen History alcohol drug abuse within past 2 year consumes 1 ( woman ) 2 ( men ) alcoholic beverage ( ) per day Tobacco cannabis smoke 3 day per week History keloid formation Positive urine test illicit drug ( opiate , cocaine , amphetamine ) screen History evidence physical examination systemic disease acute chronic illness , opinion investigator , may interfere evaluation safety immunogenicity vaccine , include axillary lymphadenopathy All female subject : currently pregnant lactating/nursing ; positive urine pregnancy test screen positive urine pregnancy test day study injection Received tuberculin skin test within 3 month ( 90 day ) prior time randomization Any current medical , psychiatric , occupational , substance abuse problem , opinion investigator , make unlikely subject comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TB</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Vaccine</keyword>
</DOC>